Teva Pharmaceuticals, the generics powerhouse, has been slapped with a hefty fine of €462.6 million by the European Commission for anti-competitive practices related to its blockbuster multiple sclerosis drug, Copaxone. The fine marks one of the largest penalties imposed on a pharmaceutical company for breaching antitrust regulations in recent years, surpassing the penalty imposed on […]
Servier has wrapped up its previously announced acquisition of Symphogen, a Danish antibody discovery company, for an undisclosed price. The French pharma company signed the deal in April 2020 with a bid to ramp up its antibody capabilities while ensuring that its own antibody discovery and early-development platform is completely leveraged. Through the acquisition, Servier will […]
Servier acquisition of Symphogen : French pharma company Servier has agreed to acquire Danish antibody discovery company Symphogen, for an undisclosed price to boost its antibody capabilities while ensuring that its own antibody discovery and early-development platform is fully leveraged. As part of the deal, Servier will get access to Symphogen’s oncology and immune-oncology pipeline […]
Pixuvri EMA approval : French pharma company Servier has secured full approval for Pixuvri (pixantrone) from the European Commission (EC) as monotherapy for aggressive non-Hodgkin B-cell lymphoma (NHL) in adult patients whose condition is multiply relapsed or refractory. Pixuvri EMA approval Since 2012, Pixantrone has been available in Europe to patients following conditional approval, which […]
The UCART19 lymphoblastic leukemia drug jointly developed by Servier and Pfizer has been given the FDA clearance for its clinical development for lymphoblastic leukemia treatment.
Servier and Pfizer Inc. have received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to proceed with the clinical development of UCART19, an innovative gene-edited therapy for the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL). Groundbreaking Gene-Edited Therapy UCART19, a chimeric antigen receptor (CAR) T-cell therapy, targets CD19-expressing hematological malignancies […]